Category Archives: Press Releases

Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics

Sydney, Australia 2 December 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health (NYSE: CAH), are pleased to announce that the companies have entered into an agreement covering Clarity’s Targeted Copper Theranostics (TCT) platform. Cardinal Health will provide cGMP product manufacturing…

Fifty percent recruitment milestone for PROPELLER prostate cancer trial

Sydney, Australia 1 December 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that 15 of 30 participants have been recruited in the diagnostic 64Cu SAR-bisPSMA clinical trial (PROPELLER) in patients with untreated, confirmed prostate…

Clarity strengthens patent protection of SAR-bisPSMA

Sydney, Australia 26 November 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the patent application covering formulations of Clarity’s optimised Prostate Specific Membrane Antigen (PSMA) targeting agent, SAR-bisPSMA, has entered the national phase…

Clarity launches partnership with Story Factory

Sydney, Australia 16 November 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce the launch of a partnership with Story Factory, a not-for-profit creative writing centre for young people in under-resourced communities across Sydney and…

Recruitment for the dosimetry phase of Clarity’s Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed

Sydney, Australia 10 November 2021 Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)1 investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resistant prostate cancer (mCRPC). Dosimetry data is being prepared for Safety Review Committee before moving into therapeutic applications with 67Cu SAR-bisPSMA therapy. Clarity shares…

Recruitment on C-BOBCAT pilot cancer trial closed for Clarity’s SAR-Bombesin product

Sydney, Australia 19 October 2021 C-BOBCAT breast cancer trial of Clarity’s SAR-Bombesin product closes for recruitment. The diagnostic program with 64Cu SAR-Bombesin generated evidence of the utility and potential superiority in some patient subgroups compared to conventional imaging (e.g. 99mTc bone scan, 18F FDG). The high uptake and strong product retention visualised by PET imaging…

Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US clinical trials

30 September 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and Evergreen Theragnostics, Inc. (“Evergreen”), a radiopharmaceutical contract manufacturer, are pleased to announce that the companies have entered into a Targeted Copper Theranostics (TCTs) manufacturing agreement for Clarity’s US clinical trials.…

Clarity joins the Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR)

22 September 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that it is now a member and will hold a Board position on the Council on Radionuclides and Radiopharmaceuticals, Inc (CORAR), a trade association…

Clarity Pharmaceuticals lists on the ASX

Sydney, Australia 25 August 2021 Clarity Pharmaceuticals lists on the ASX today under code CU6 after raising $92.0 million at $1.40 per share, equating to an indicative market capitalisation of approximately $358.6million (on an undiluted basis) at the Offer price. Clarity is an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing…

First patient treated in Clarity’s Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial

Sydney, Australia 25 August 2021 – Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the first US patient has been dosed with 64Cu SAR-bisPSMA in the dosimetry phase of the SECuRE clinical trial (NCT04868604)1…